ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00% | 9.62% | 9.62% | 20.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00% | 9.62% | 9.62% | 20.49% |
| Cost of Revenue | -- | -38.98% | -42.13% | -42.13% | -41.50% |
| Gross Profit | -- | 48.14% | 53.37% | 53.37% | 53.60% |
| SG&A Expenses | -- | -28.97% | -32.41% | -32.41% | -30.47% |
| Depreciation & Amortization | -- | -5.96% | -7.40% | -7.40% | -1.82% |
| Other Operating Expenses | -- | 0.25% | 5.95% | 5.95% | 32.99% |
| Total Operating Expenses | -- | -23.68% | -21.45% | -21.45% | -19.54% |
| Operating Income | -- | 24.24% | 22.14% | 22.14% | 20.33% |
| Income Before Tax | -- | 17.93% | 17.79% | 17.79% | 24.78% |
| Income Tax Expenses | -- | 66.11% | 65.84% | 65.84% | 65.58% |
| Earnings from Continuing Operations | -- | 10.23% | 10.17% | 10.17% | 19.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 10.23% | 10.17% | 10.17% | 19.02% |
| EBIT | -- | 24.24% | 22.14% | 22.14% | 20.33% |
| EBITDA | -- | 26.74% | 24.06% | 24.06% | 22.77% |
| EPS Basic | -- | 15.53% | 15.07% | 15.07% | 31.12% |
| Normalized Basic EPS | -- | 29.75% | 28.56% | 28.56% | 42.46% |
| EPS Diluted | -- | 15.75% | 15.93% | 15.93% | 31.31% |
| Normalized Diluted EPS | -- | 29.75% | 28.56% | 28.56% | 42.46% |
| Average Basic Shares Outstanding | -- | 6.47% | 5.32% | 5.32% | 13.77% |
| Average Diluted Shares Outstanding | -- | 6.47% | 5.32% | 5.32% | 13.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |